ClinicalTrials.gov
public full text
Public Domain
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients#405114
- PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma#1096250
- A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients#208413
- Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma#1282768
- Vemurafenib and White Blood Cell Therapy for Advanced Melanoma#668830
Record · ID 1395055
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive